STAT Plus: Pharmalittle: Canada may change new rules for drug prices; Trump frustrated over drug pricing
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still evolving, but for now, we hope to tend to some sundry chores, catch up on our napping, and hang with a short person or two. And what about you? This may be a good opportunity to take in a moving picture or peruse the inventory in your local library. You could catch up with someone special. Or perhaps this is a good time to finish your taxes, since the Treasury could use the funds to cover golf outings. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.
Canada is considering significant changes to how it will apply new regulations aimed at lowering costs, as unhappy drug makers delay product launches and blame it for job cuts, Reuters reports. In August, the government passed new regulations for patented drugs despite lobbying from drug makers. The rules base Canadian prices on those from a group of countries with lower prices than a benchmark group now used to set ceilings, and give regulators the power to review new medicines based on cost-effectiveness.
Continue to STAT Plus to read the full story…
